Westover Capital Advisors LLC lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,214 shares of the company’s stock after acquiring an additional 172 shares during the period. Westover Capital Advisors LLC’s holdings in Medpace were worth $2,147,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC lifted its position in Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after purchasing an additional 26 shares during the period. Commonwealth Equity Services LLC lifted its holdings in shares of Medpace by 0.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after buying an additional 32 shares during the period. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Medpace by 5.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock worth $316,000 after buying an additional 39 shares during the last quarter. Journey Advisory Group LLC grew its holdings in shares of Medpace by 1.9% in the second quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock worth $984,000 after acquiring an additional 44 shares during the period. Finally, Coldstream Capital Management Inc. grew its holdings in shares of Medpace by 5.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock worth $292,000 after acquiring an additional 45 shares during the period. 77.98% of the stock is owned by institutional investors.
Medpace Stock Up 2.0 %
Shares of NASDAQ:MEDP opened at $351.67 on Friday. The firm has a fifty day simple moving average of $384.27 and a two-hundred day simple moving average of $393.43. Medpace Holdings, Inc. has a 52 week low of $227.21 and a 52 week high of $459.77. The stock has a market capitalization of $10.90 billion, a P/E ratio of 35.85, a PEG ratio of 1.74 and a beta of 1.35.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on MEDP shares. TD Cowen cut their price target on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research note on Wednesday, July 24th. Guggenheim reduced their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Mizuho started coverage on shares of Medpace in a research note on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target on the stock. Robert W. Baird cut their price objective on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating for the company in a research report on Wednesday, July 24th. Finally, William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Wednesday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $423.00.
Check Out Our Latest Report on MEDP
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Recommended Stories
- Five stocks we like better than Medpace
- How to Calculate Inflation Rate
- MarketBeat Week in Review – 9/9 – 9/13
- How to Evaluate a Stock Before Buying
- Dividend Stocks to Buy Now for High Yield
- Best Stocks Under $10.00
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.